This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: Catechol-O-methyltransferase (COMT), an enzyme that catalyzes the degradation of dopamine, is necessary for cognitive function. Few studies have examined the prospective association between COMT (val158met) genotype and cognition in older adults.
Methods: We assessed a biracial cohort of 2,858 elderly subjects without dementia who were followed for 8 years. The Modified Mini-Mental State Examination (3MS) and Digit Symbol Substitution Test (DSST) were administered at baseline and years 3, 5, and 8. COMT by race, gender, and APOE status interactions were examined.
Results: Stratified by race and adjusted for covariates, repeated-measures mixed-effects models showed no association between COMT genotype and baseline cognitive function in black or white subjects. In white subjects, COMT was associated with change in 3MS (Met/Met: −2.3 [0.60], Met/Val: −1.7 [0.40], and Val/Val: −1.2 [0.50]) and DSST (Met/Met: −5.60 [1.00], Met/Val: −4.80 [0.70], Val/Val: −4.00 [0.90]). In black subjects, COMT was associated with change in the DSST (Met/Met: −4.10 [2.1], Met/Val: −4.80 [0.90], Val/Val −2.60 [1.00]).
Conclusion: These findings suggest that the Val allele has a protective impact on cognitive decline in late life.
Glossary
- 3MS=
- Modified Mini-Mental State Examination;
- BMI=
- body mass index;
- CES-D=
- Center for Epidemiologic Studies–Depression Scale;
- COMT=
- catechol-O-methyltransferase;
- DSST=
- Digit Symbol Substitution Test;
- Health ABC=
- Health Aging and Body Composition;
- PFC=
- prefrontal cortex.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Differences in Age-related Retinal and Cortical Atrophy Rates in Multiple Sclerosis
Prof. Massimo Filippi and Dr. Paolo Preziosa
► Watch
Topics Discussed
Alert Me
Recommended articles
Cardiovascular Risk Factors Across the Life Course and Cognitive Decline
Retinal signs and 20-year cognitive decline in the Atherosclerosis Risk in Communities Study
Vascular and dopaminergic contributors to mild parkinsonian signs in older adults
APOE genotype and cognitive decline in a middle-aged cohort